Monika Krasoń

Monika Krasoń

Auto-generated profile, based on publicly available information

Monika Krasoń

Central Teaching Hospital of the Medical University of Lodz, ul. Pomorska 251, 92-213 Łódź, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MKMikolaj Kurczynski
Mikolaj Kurczynski
ASAleksandra Suszczyńska
Aleksandra Suszczyńska
AWAngelika Wiatr
Angelika Wiatr
KJKsenia Jakubiak
Ksenia Jakubiak
JWJulia Witkowska
Julia Witkowska
MKMonika Krasoń
Monika Krasoń
The foundation of current prostate cancer diagnostics still remains the interpretation of total PSA (tPSA) results, but it is an imperfect test due to its low specificity and diagnostic ambiguities in patients within the "gray zone," meaning patients with a result of (2.0/4.0–10.0 ng/mL). This fact leads to many cases of "overdiagnosis" and an excess of unnecessarily performed biopsies. This article summarizes the diagnostic value of blood-based biomarkers and tests (PHI, 4Kscore, Stockholm3) as well as urine-based ones (SelectMDx and ExoDx). These tests achieve high AUC values (0.76–0.88) and a high negative predictive value (up to 98%) in detecting clinically significant prostate cancer (csPCa, GG ≥ 2), underscoring their advantage over traditional methods. Combining them with multiparametric MRI allows for a 30–65% reduction in unnecessary biopsies while maintaining high oncological safety for the patient. Despite promising results, the high costs of individual tests, lack of reimbursement, and absence of full standardization in international urological guidelines remain a continuous challenge and a hurdle to their introduction into daily practice.